Plasma IL-1β Concentration Associates with Sleep Quality and Cognitive Functions in Men with Prostate Cancer.

Summary: Men undergoing hormone therapy for prostate cancer often face hidden battles with sleep and mental sharpness. A new study reveals that a specific inflammation marker in the blood, known as IL-1β, acts as a "red flag" for these issues. Patients with metastatic cancer had worse sleep than those with localized disease, and higher levels of this inflammation marker were strongly linked to severe insomnia and cognitive changes. By monitoring this simple biomarker, nurses and doctors may be able to better identify patients struggling with sleep and tailor treatments to improve their quality of life.